NCT06515587View on ClinicalTrials.gov

Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

October 31, 2026

Conditions
PDAC
Interventions
DIAGNOSTIC_TEST

Lewis genotype detection reagent

By evaluating the results of the Lewis gene test combined with the CA19-9 test, different subtypes of pancreatic cancer patients were differentiated to evaluate the prognosis

Trial Locations (1)

200040

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER